Reappraisal of immunologic mechanisms of hypomethylating agents in treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia

被引：0
|
作者：
Hong, Junshik
Min, Suji
Park, Jihyun
Fielder, Carly M.
Hu, Qianni
Yoon, Sung-Soo
Kim, Tae Kon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3269
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Acute myeloid leukemia of the elderly:: results of induction after previous treatment of high-risk myelodysplastic syndrome with a demethylating agent
    Lübbert, M
    Wijermans, PW
    Licht, T
    Jones, PA
    BLOOD, 2003, 101 (04) : 1657 - 1658
  • [32] Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Tang, Man Wai
    van der Tuin, Deborah
    Aydin, Mesire
    Heijmans, Jarom
    van de Loosdrecht, Arjan A.
    Meijer, Ellen
    Rutten, Caroline E.
    Wondergem, Marielle
    Janssen, Jeroen J. W. M.
    Donker, Marjolein L.
    Hazenberg, Mette D.
    Zweegman, Sonja
    Biemond, Bart J.
    De Leeuw, David C.
    Nur, Erfan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 620 - 625
  • [33] The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs
    Short, Nicholas J.
    Dombret, Herve
    Ades, Lionel
    Kantarjian, Hagop
    CANCER JOURNAL, 2022, 28 (01): : 29 - 36
  • [34] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [35] Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis
    Jabbour, Elias
    Ghanem, Hady
    Huang, Xuelin
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Faded, Stephan
    Pierce, Sherry
    Choi, Sangbum
    Verstovsek, Srdan
    Brandt, Mark
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (02): : 93 - 97
  • [36] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Naval Daver
    Prajwal Boddu
    Guillermo Garcia-Manero
    Shalini Singh Yadav
    Padmanee Sharma
    James Allison
    Hagop Kantarjian
    Leukemia, 2018, 32 : 1094 - 1105
  • [37] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Daver, Naval
    Boddu, Prajwal
    Garcia-Manero, Guillermo
    Yadav, Shalini Singh
    Sharman, Padmanee
    Allison, James
    Kantarjian, Hagop
    LEUKEMIA, 2018, 32 (05) : 1094 - 1105
  • [38] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [39] Evaluating Venetoclax Treatment Duration When Combined with Hypomethylating Agents in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
    Uchida, Emma
    Lei, Matthew M.
    Brunner, Andrew M.
    Fathi, Amir T.
    Signorelli, Jessie
    BLOOD, 2021, 138
  • [40] A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Becker, Pamela S.
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland B.
    Estey, Elihu H.
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1023 - 1029
12345